Опубликована: Янв. 1, 2024
Язык: Английский
Опубликована: Янв. 1, 2024
Язык: Английский
European Journal of Medicinal Chemistry, Год журнала: 2025, Номер 288, С. 117382 - 117382
Опубликована: Фев. 16, 2025
Язык: Английский
Процитировано
1The EPMA Journal, Год журнала: 2025, Номер unknown
Опубликована: Апрель 10, 2025
Cancer drug resistance poses a significant challenge in oncology, primarily driven by cancer cell plasticity, which promotes tumor initiation, progression, metastasis, and therapeutic evasion many different cancers. Breast cancers (BCs) are prominent example of that, with an estimated 2.3 million new cases 670,000 BC-related deaths registered worldwide annually. Triple-negative BC is especially challenging for treatments demonstrating particularly aggressive disease course, early manifestation metastatic disease, frequent drug-resistant types, poor individual outcomes. Although chemosensitizing agents have been developed, their clinical utility oncology remains unproven. The mitogen-activated protein kinase (MAPK) pathway considered critical regulator intracellular extracellular signaling highly relevant both - genetic epigenetic modifications. Dysregulation the MAPK pathways plays role conferring chemoresistance BC. Contextually, targeting represents promising strategy overcoming enhancing efficacy anticancer treatment. On other hand, flavonoids, class phytochemicals, key modulators signaling. Flavonoids interact ERK, JNK, p38, ERK5 cascade present avenue developing novel anti-cancer therapies re-sensitizing treatment Compounds such as quercetin, kaempferol, genistein, luteolin, myricetin, EGCG, baicalein, baicalin, nobiletin, morin, delphinidin, acacetin, isorhamnetin, apigenin, silymarin, among others, identified specific signaling, exerting complex downstream effects cells increasing therewith suppressing growth aggressivity. These properties reflect mechanisms great relevance to overcome overall management. This article highlights corresponding provides clinically illustrations framework 3P medicine primary (protection individuals at high risk against health-to-disease transition) secondary care progression). 3PM novelty makes good use patient phenotyping stratification, predictive multi-level diagnostics, application Artificial Intelligence (AI) tools individualized interpretation big data all proposed cost-effective tailored profiles clear benefits patients advanced
Язык: Английский
Процитировано
1Journal of Molecular Structure, Год журнала: 2025, Номер unknown, С. 141506 - 141506
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0Phytochemistry Reviews, Год журнала: 2025, Номер unknown
Опубликована: Март 11, 2025
Язык: Английский
Процитировано
0International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(18), С. 10066 - 10066
Опубликована: Сен. 19, 2024
This study investigated the therapeutic potential of licochalcone D (LicoD), which is derived from Glycyrrhiza uralensis, for improving glucose metabolism in AML12 hepatocytes with high-glucose-induced insulin resistance (IR). Ultra-high-performance liquid chromatography–mass spectrometry revealed that LicoD content G. uralensis was 8.61 µg/100 mg ethanol extract (GUE) and 0.85 hot water extract. GUE enhanced consumption uptake, as well Glut2 mRNA expression, IR cells. These effects were associated activation receptor substrate/phosphatidylinositol-3 kinase signaling pathway, increased protein B α phosphorylation, suppression gluconeogenesis-related genes, such Pepck G6pase. Furthermore, promoted glycogen synthesis by downregulating phosphorylase. mitigated downregulated expression mitochondrial oxidative phosphorylation proteins activating PPARα/PGC1α pathway increasing DNA content. findings demonstrate options alleviating IR-induced metabolic disorders function.
Язык: Английский
Процитировано
2Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0